

well

HAN-GINS Indxx Healthcare Innovation UCITS ETF - Acc

Factsheet | Data as of 30 Sep 2020

Investment Objective

HAN-GINS Indxx Healthcare Innovation UCITS ETF (WELL) is a UCITS compliant Exchange Traded Fund domiciled in Ireland. WELL tracks the Indxx Advanced Life Sciences & Smart Healthcare Thematic Index (Net Total Return), an index designed to measure the performance of performance of large, mid and small-capitalisation companies primarily listed on an exchange in Developed and Emerging Markets that are involved in the Advanced Life Sciences & Smart Healthcare sector.

Why WELL?



Transparent, Modern Approach:

WELL follows a transparent rules-based, free-float weighed index ensuring only investible companies are included within the ETF.



Diversified:

In a single trade, WELL provides access to a basket of companies from Developed and Emerging markets with high exposure to the healthcare innovation theme.



Unconstrained Approach:

WELL transcends traditional industry and sector classifications to provide exposure to an emerging theme.

Key Risks

1. The value of equities and equity-related securities can be affected by daily stock and currency market movements
2. Thematic ETFs are exposed to a limited number of sectors and thus the investment will be concentrated and may experience high volatility
3. Investors' capital is fully at risk and may not get back the amount originally invested
4. Exchange rates can have a positive or negative effect on returns
5. Further risks are disclosed in the KIID and Prospectus

Performance vs Index

Fund	1M	3M	6M	YTD	12M
WELL	-1.05%	7.30%	33.03%	15.37%	32.24%
IELXRNT	-0.97%	7.43%	33.56%	16.09%	33.40%

Source: Bloomberg, as of 30 Sep 2020. Performance for the fund and the index is shown in USD. Fund performance is shown net of fees with income reinvested where applicable. Please be aware that fees have a detrimental impact on the performance of an ETP. Past performance is not an indicator for future results.

Trading Information

Exchange	Ticker	RIC	SEDOL	ISIN	CCY
LSE	WELL LN	HAWELL.L	BJVBGL7	IE00BJQTJ848	USD
LSE	WELP LN	WELP.L	BJVBGM8	IE00BJQTJ848	GBP
Borsa Italiana	WELL IM	WELL.MI	BHRWXD1	IE00BJQTJ848	EUR
Xetra	W311.GY	W311.DE	BJO2354	IE00BJQTJ848	EUR
SIX	WELL SW	WELL.S	BMYC3R3	IE00BJQTJ848	CHF

Key Facts

Inception Date	04/04/2019
Index	Indxx Advanced Life Sciences & Smart Healthcare Healthcare Thematic Index
Asset Class	Equities
Number of Holdings	107
Base Currency	USD
Index PE Ratio	96.71
Index Dividend Yield (Est)	0.32%
Income Treatment	Accumulating
TER	59 bps
Rebalance Frequency	Annually, June
Fund Domicile	Ireland
Replication Style	Physical
Registered for Sale	UK, IE, IT, DE, AT, DK, FI, LU, NL, NO, SE, CH
Fund Reporting Status	Yes
UCITS Eligible	Yes
ISA Eligible	Yes
SIPP Eligible	Yes
Custodian	BNY Mellon
Portfolio Manager	Vident Investment Advisory, LLC
Net Assets of Fund	9,561,269.18 (USD)
Net Assets of Share Class	9,561,269.18 (USD)
Shares Outstanding	960,000

Index Information

Indxx Advanced Life Sciences & Smart Healthcare Thematic Index (Net Total Return) is managed according to a published, rules-based methodology. It is designed to measure the performance of an investable universe of publicly-traded companies that are involved in healthcare innovation. To be included, companies must derive revenue from themes including Robotics, Nanotechnology, Genome Sequencing, Healthcare Trackers, Biological Engineering , Bioinformatics, Neuroscience, Medical Devices For further information, visit www.Indxx.com

Index Performance and Volatility Indicators (USD)

Period	Return	Volatility
2015	12.72%	17.52%
2016	0.12%	17.58%
2017	34.28%	9.92%
2018	6.62%	19.20%
2019*	25.40%	13.73%
2020	15.37%	32.27%


*Index data up to the 03/04/2019. Fund data from 04/04/2019

Performance before inception is based on back tested data. Back testing is the process of evaluating an investment strategy by applying it to historical data to simulate what the performance of that strategy would have been. Back tested data does not represent actual performance and should not be interpreted as an indication of actual or future performance. Past performance for the index is in USD and shown net of fees. Past performance and back tested index performance is not an indicator for future results and should not be the sole factor of consideration when selecting a product. It is provided for illustrative purposes only. Indices cannot be invested in directly. Investors should read the prospectus of the Issuer ("Prospectus") before investing and should refer to the section of the Prospectus entitled 'Risk Factors' for further details of risks associated with an investment in this product. Source HANetf /Indxx.

Top 10 Index Holdings (%)

Company	(%)	Company	(%)
Intuitive Surgical Inc	5.08%	DexCom Inc	4.19%
Edwards Lifesciences Corp	4.75%	Regeneron Pharmaceuticals Inc	3.75%
Medtronic PLC	4.69%	Illumina Inc	3.55%
Biogen Inc	4.45%	Agilent Technologies Inc	3.45%
Boston Scientific Corp	4.44%	Zimmer Biomet Holdings Inc	3.12%

Regional Exposure



Sub-Theme Breakdown

Sector	Weight (%)
Medical Devices	56.84%
Biological Engineering	23.17%
Neuroscience	6.68%
Genome Sequencing	5.53%
Robotics	5.13%
Healthcare Tracker	2.44%
Bioinformatics	0.19%

ETF Partner

HAN-GINS Indxx Healthcare Innovation UCITS ETF has been developed by HANetf and Gins Global Investment Management, a multi-billion dollar asset management company founded in 2000 with operations in North America, Africa, Middle East and Asia-Pacific. www.ginsglobal.com



About HANetf

HANetf is an independent provider of UCITS ETFs, working with asset management companies to bring differentiated, modern and innovative exposures to European ETF investors. Via our white-label ETF platform, HANetf provides a complete operational, regulatory, distribution and marketing solution for asset managers to launch and manage UCITS ETFs.

IMPORTANT INFORMATION This factsheet is approved for professional use only. The exchange traded fund ("ETF") to which it relates is a UCITS fund and accordingly is available for purchase by all investor types, including retail and professional investors. The content in this document is issued by HANetf Limited ("HANetf"), an appointed representative of Mirabella Advisers LLP, which is authorised and regulated by the Financial Conduct Authority ("FCA").

HANetf ICAV is an open-ended Irish collective asset management vehicle which is constituted as an umbrella fund with segregated liability between sub-funds and with variable capital organised under the laws of Ireland and authorised by the Central Bank of Ireland. Investors should read the prospectus of HANetf ICAV ("Prospectus") before investing and should refer to the section of the Prospectus entitled 'Risk Factors' for further details of risks associated with an investment in the Shares. Any decision to invest should be based on the information contained in the Prospectus and after seeking independent investment, tax and legal advice.

Past performance is not a reliable indicator of future performance. Any historical performance included on this document may be based on back testing. Back testing is the process of evaluating an investment strategy by applying it to historical data to simulate what the performance of such strategy would have been. Back tested performance is purely hypothetical and is provided on this document solely for informational purposes. Back tested data does not represent actual performance and should not be interpreted as an indication of actual or future performance. The value of any investment may be affected by exchange rate movements. An investment in an ETF is dependent on the performance of the underlying index, less costs, but it is not expected to match that performance precisely.

This ETF may not be available in your market or suitable for you. The content of this document does not constitute investment advice nor an offer for sale nor a solicitation of an offer to buy any product or make any investment. The information contained on this document is not, and under no circumstances is to be construed as, an advertisement or any other step in furtherance of a public offering of shares in the United States or any province or territory thereof, where HANetf ICAV or the ETF are authorised or registered for distribution and where no Prospectus has been filed with any securities commission or regulatory authority. No document or information on this document should be taken, transmitted or distributed (directly or indirectly) into the United States. HANetf ICAV, nor any securities issued by it, has been or will be registered under the United States Securities Act of 1933 or the Investment Company Act of 1940 or qualified under any applicable state securities statutes.

This document may contain forward looking statements including statements regarding our belief or current expectations with regards to the performance of certain assets classes and/or sectors. Forward looking statements are subject to certain risks, uncertainties and assumptions. There can be no assurance that such statements will be accurate and actual results could differ materially from those anticipated in such statements. Therefore, readers are cautioned not to place undue reliance on these forward-looking statements.

ETFs involve numerous risks including among others, general market risks relating to the relevant underlying index, exchange rate risks, interest rate risks, inflationary risks, liquidity risks and legal and regulatory risks.

FOR SWISS INVESTORS ONLY: The Fund has appointed as Swiss Representative Oligo Swiss Fund Services SA, Av. Villamont 17, 1005 Lausanne, Switzerland, Te l: +41 21 311 17 77, email: info@oligofunds.ch. The Fund's Swiss paying agent is Helvetische Bank AG. The Prospectus, the Key Investor Information Documents, the Instrument of Incorporation as well as the annual and semi-annual reports may be obtained free of charge from the Swiss Representative in Lausanne. In respect of the Shares distributed in or from Switzerland, the place of performance and jurisdiction is at the registered office of the Swiss Representative. The issue and redemption prices are published at each issue and redemption on www.fundinfo.com This key investor information is accurate as at 1 May 2020.